A Saul

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. pmc Transmission-blocking activity induced by malaria vaccine candidates Pfs25/Pvs25 is a direct and predictable function of antibody titer
    Kazutoyo Miura
    Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, USA
    Malar J 6:107. 2007
  2. pmc Induction of multi-antigen multi-stage immune responses against Plasmodium falciparum in rhesus monkeys, in the absence of antigen interference, with heterologous DNA prime/poxvirus boost immunization
    George Jiang
    Malaria Program, Naval Medical Research Center, Silver Spring, MD 20910 7500, USA
    Malar J 6:135. 2007
  3. pmc Can mutation and selection explain virulence in human P. falciparum infections?
    Ian M Hastings
    Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, UK
    Malar J 3:2. 2004
  4. ncbi request reprint Models of Phase 1 vaccine trials: optimization of trial design to minimize risks of multiple serious adverse events
    Allan Saul
    Malaria Vaccine Development Branch NIAID NIH, 5460 Fishers Lane, Room 1113, Twinbrook I, Rockville, MD 20852, USA
    Vaccine 23:3068-75. 2005
  5. pmc Zooprophylaxis or zoopotentiation: the outcome of introducing animals on vector transmission is highly dependent on the mosquito mortality while searching
    Allan Saul
    Malaria Vaccine Development Unit, NIAID, NIH, Rockville, MD 20852, USA
    Malar J 2:32. 2003
  6. ncbi request reprint Immunogenicity in rhesus of the Plasmodium vivax mosquito stage antigen Pvs25H with Alhydrogel and Montanide ISA 720
    A Saul
    Malaria Vaccine Development Branch, National Institutes of Health, Rockville, MD 20852, USA
    Parasite Immunol 29:525-33. 2007
  7. ncbi request reprint A human phase 1 vaccine clinical trial of the Plasmodium falciparum malaria vaccine candidate apical membrane antigen 1 in Montanide ISA720 adjuvant
    Allan Saul
    The Cooperative Research Centre for Vaccine Technology, Brisbane, QLD, Australia
    Vaccine 23:3076-83. 2005
  8. pmc Human immunity and the design of multi-component, single target vaccines
    Allan Saul
    Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, United States of America
    PLoS ONE 2:e850. 2007
  9. ncbi request reprint Mosquito stage, transmission blocking vaccines for malaria
    Allan Saul
    Laboratory of Malaria and Vector Biology, NIAID, NIH, Rockville, Maryland 20852, USA
    Curr Opin Infect Dis 20:476-81. 2007
  10. pmc Addition of CpG ODN to recombinant Pseudomonas aeruginosa ExoProtein A conjugates of AMA1 and Pfs25 greatly increases the number of responders
    Feng Qian
    Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA
    Vaccine 26:2521-7. 2008

Detail Information

Publications70

  1. pmc Transmission-blocking activity induced by malaria vaccine candidates Pfs25/Pvs25 is a direct and predictable function of antibody titer
    Kazutoyo Miura
    Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, USA
    Malar J 6:107. 2007
    ..A clear understanding of the relationship between antibody levels and TBA may allow ELISA determinations to be used to predict TBA and assist in planning vaccine development...
  2. pmc Induction of multi-antigen multi-stage immune responses against Plasmodium falciparum in rhesus monkeys, in the absence of antigen interference, with heterologous DNA prime/poxvirus boost immunization
    George Jiang
    Malaria Program, Naval Medical Research Center, Silver Spring, MD 20910 7500, USA
    Malar J 6:135. 2007
    ....
  3. pmc Can mutation and selection explain virulence in human P. falciparum infections?
    Ian M Hastings
    Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, UK
    Malar J 3:2. 2004
    ..Parasites incur periodic mutations which must ultimately be eliminated to maintain their genetic integrity...
  4. ncbi request reprint Models of Phase 1 vaccine trials: optimization of trial design to minimize risks of multiple serious adverse events
    Allan Saul
    Malaria Vaccine Development Branch NIAID NIH, 5460 Fishers Lane, Room 1113, Twinbrook I, Rockville, MD 20852, USA
    Vaccine 23:3068-75. 2005
    ....
  5. pmc Zooprophylaxis or zoopotentiation: the outcome of introducing animals on vector transmission is highly dependent on the mosquito mortality while searching
    Allan Saul
    Malaria Vaccine Development Unit, NIAID, NIH, Rockville, MD 20852, USA
    Malar J 2:32. 2003
    ..However, as the number of animals increases, improved availability of blood meals may increase mosquito survival, thereby countering the impact of diverting feeds...
  6. ncbi request reprint Immunogenicity in rhesus of the Plasmodium vivax mosquito stage antigen Pvs25H with Alhydrogel and Montanide ISA 720
    A Saul
    Malaria Vaccine Development Branch, National Institutes of Health, Rockville, MD 20852, USA
    Parasite Immunol 29:525-33. 2007
    ..vivax to mosquitoes. Antibody titres and transmission blocking were higher with Montanide ISA 720 than with Alhydrogel in the first trial and with the 15 microg Pvs25H/0.5 mL ISA 720 combination in the second trial...
  7. ncbi request reprint A human phase 1 vaccine clinical trial of the Plasmodium falciparum malaria vaccine candidate apical membrane antigen 1 in Montanide ISA720 adjuvant
    Allan Saul
    The Cooperative Research Centre for Vaccine Technology, Brisbane, QLD, Australia
    Vaccine 23:3076-83. 2005
    ..Six of the 29 subjects seroconverted. Only one of these developed a high antibody titre. However, the interpretation of this trial was compromised by a loss of potency of the formulated vaccine during the course of the study...
  8. pmc Human immunity and the design of multi-component, single target vaccines
    Allan Saul
    Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, United States of America
    PLoS ONE 2:e850. 2007
    ..As a consequence, there is little practical experience for deciding where the increased complexity of vaccines with multiple defined immunogens vaccines targeting single pathogens will be justifiable...
  9. ncbi request reprint Mosquito stage, transmission blocking vaccines for malaria
    Allan Saul
    Laboratory of Malaria and Vector Biology, NIAID, NIH, Rockville, Maryland 20852, USA
    Curr Opin Infect Dis 20:476-81. 2007
    ..This review highlights progress made in the development of vaccines aimed at the stages of malaria parasites found in mosquitoes that block the transmission of malaria within a community...
  10. pmc Addition of CpG ODN to recombinant Pseudomonas aeruginosa ExoProtein A conjugates of AMA1 and Pfs25 greatly increases the number of responders
    Feng Qian
    Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA
    Vaccine 26:2521-7. 2008
    ..The results obtained in this study indicate the potential use of a combination strategy to increase the number of responders to malarial antigens in humans...
  11. pmc In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response
    Michael C Kennedy
    Malaria Vaccine Development Unit, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland 20852, USA
    Infect Immun 70:6948-60. 2002
    ....
  12. ncbi request reprint Large-scale purification and characterization of malaria vaccine candidate antigen Pvs25H for use in clinical trials
    Aaron P Miles
    Malaria Vaccine Development Unit, National Institute of Allergy and Infectious Diseases, Rockville, Maryland 20852, USA
    Protein Expr Purif 25:87-96. 2002
    ..We report here a procedure for successfully separating these two forms with a process suitable for clinical production of this antigen...
  13. pmc Vaccination of monkeys with recombinant Plasmodium falciparum apical membrane antigen 1 confers protection against blood-stage malaria
    Anthony W Stowers
    Malaria Vaccine Development Unit, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland 20852, USA
    Infect Immun 70:6961-7. 2002
    ..The protection induced by a combination vaccine of AMA1 and MSP1 was not superior to the protection obtained with AMA1 alone, although the immunity generated appeared to operate against both vaccine components...
  14. doi request reprint Efficacy model for mosquito stage transmission blocking vaccines for malaria
    A Saul
    Laboratory of Malaria and Vector Research, NIAID, and Epidemiology and Population Studies, Fogarty International Center, NIH, 12735 Twinbrook Parkway, Rockville MD 20852, USA
    Parasitology 135:1497-506. 2008
    ..The model predicts that current formulations of Pfs25 are likely to achieve useful reductions in transmission when tested in human field trials...
  15. pmc Enhanced antibody production in mice to the malaria antigen AMA1 by CPG 7909 requires physical association of CpG and antigen
    Gregory E D Mullen
    Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5640 Fishers Lane, Rockville, MD 20852, USA
    Vaccine 25:5343-7. 2007
    ..Our results suggest that the adjuvant effects of CpGs are optimal when adsorbed to Alhydrogel and highlight the need for careful characterization of the vaccine formulation...
  16. pmc posttranslational modification of recombinant Plasmodium falciparum apical membrane antigen 1: impact on functional immune responses to a malaria vaccine candidate
    Birgitte Giersing
    Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, Twinbrook I, Room 1210A, 5640 Fisher Lane, Rockville, Maryland 20852, USA
    Infect Immun 73:3963-70. 2005
    ..coli- and P. pastoris-derived antigens are immunologically and functionally equivalent and are unaffected by the posttranslational modification resulting from expression in these two systems...
  17. ncbi request reprint Antibodies to Plasmodium vivax transmission-blocking vaccine candidate antigens Pvs25 and Pvs28 do not show synergism
    H Hisaeda
    Malaria Vaccine Development Unit, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5640 Fishers Lane, Rockville, MD 20852, USA
    Vaccine 20:763-70. 2001
    ..vivax between anti-Pvs25 and anti-Pvs28 antibodies...
  18. pmc Characterization of a protective Escherichia coli-expressed Plasmodium falciparum merozoite surface protein 3 indicates a non-linear, multi-domain structure
    Chiawei W Tsai
    Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Disease, National Institutes of Health, Rockville, MD 20852, United States
    Mol Biochem Parasitol 164:45-56. 2009
    ..EcMSP3, which likely mimics the native MSP3 structure located on the merozoite surface, is a viable candidate for inclusion in a multi-component malaria vaccine...
  19. pmc Phase 1 trial of AMA1-C1/Alhydrogel plus CPG 7909: an asexual blood-stage vaccine for Plasmodium falciparum malaria
    Gregory E D Mullen
    Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, United States of America
    PLoS ONE 3:e2940. 2008
    ..This is the first reported use in humans of an investigational vaccine, AMA1-C1/Alhydrogel, with the novel adjuvant CPG 7909...
  20. pmc Conjugating recombinant proteins to Pseudomonas aeruginosa ExoProtein A: a strategy for enhancing immunogenicity of malaria vaccine candidates
    Feng Qian
    Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5640 Fishers Lane, Rockville, MD 20852, USA
    Vaccine 25:3923-33. 2007
    ..These conjugates now need to be tested in humans to determine if mice are predictive of the response in humans...
  21. pmc Induction of crossreactive antibodies against the Plasmodium falciparum variant protein
    Sylvie Gratepanche
    Malaria Vaccine Development Unit, National Institute of Allergy and Infectious Diseases National Institutes of Health, Rockville, MD 20852, USA
    Proc Natl Acad Sci U S A 100:13007-12. 2003
    ..The induced crossreactivity suggests that an anti-PfEMP1 vaccine may be possible...
  22. pmc Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates
    Ulrike Wille-Reece
    Cellular Immunology Section, Vaccine Research Center, National Institutes of Health, Bethesda, MD 20892, USA
    J Exp Med 203:1249-58. 2006
    ..These data provide insights for designing prime-boost immunization regimens to optimize Th1 and CD8+ T cell responses...
  23. ncbi request reprint Merozoite surface protein 3 and protection against malaria in Aotus nancymai monkeys
    Hajime Hisaeda
    Malaria Vaccine Development Unit, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases NIH, Rockville, MD 20852, USA
    J Infect Dis 185:657-64. 2002
    ..In the MSP3-vaccinated group, protection correlated with prechallenge titers of antibody to MSP3. In the MSP1 and control groups, protection correlated with antibody to MSP3 raised by challenge infection...
  24. ncbi request reprint Improved yield of recombinant merozoite Surface protein 3 (MSP3) from Pichia pastoris using chemically defined media
    Jin Wang
    Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5640 Fishers Lane, Rockville, Maryland 20852, USA
    Biotechnol Bioeng 90:838-47. 2005
    ..pastoris biomass generated at a high specific growth rate (0.04/h) nor low induction temperatures during induction improved yield. Nitrogen source was the most important factor affecting expression of MSP3 in defined media...
  25. pmc A recombinant vaccine expressed in the milk of transgenic mice protects Aotus monkeys from a lethal challenge with Plasmodium falciparum
    Anthony W Stowers
    Malaria Vaccine Development Unit, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, Rockville, MD 20852, USA
    Proc Natl Acad Sci U S A 99:339-44. 2002
    ..This study demonstrates the potential for producing efficacious malarial vaccines in transgenic animals...
  26. pmc Formulation of vaccines containing CpG oligonucleotides and alum
    Joan A Aebig
    Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5640 Fishers Lane, Rockville, MD, 20852 USA
    J Immunol Methods 323:139-46. 2007
    ..It also suggests that IP-10 assays are not a good basis for potency assays for alum-based vaccines containing CPG 7909...
  27. pmc Development and characterization of a standardized ELISA including a reference serum on each plate to detect antibodies induced by experimental malaria vaccines
    Kazutoyo Miura
    Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA
    Vaccine 26:193-200. 2008
    ..Since this ELISA method gives reliable antibody titer with less labor than other methods, it can strongly support vaccine development...
  28. pmc Sustained high-titer antibody responses induced by conjugating a malarial vaccine candidate to outer-membrane protein complex
    Yimin Wu
    Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA
    Proc Natl Acad Sci U S A 103:18243-8. 2006
    ..Protein antigen conjugation to OMPC or other protein carrier may have general application to a spectrum of protein subunit vaccines to increase immunogenicity without the need for potentially reactogenic adjuvants...
  29. ncbi request reprint Enhancement of functional antibody responses to AMA1-C1/Alhydrogel, a Plasmodium falciparum malaria vaccine, with CpG oligodeoxynucleotide
    Gregory E D Mullen
    Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5640 Fishers Lane, Rockville, MD 20852, USA
    Vaccine 24:2497-505. 2006
    ..These promising preclinical results have recently led to the start of a Phase 1 trial in the US...
  30. ncbi request reprint Aotus New World monkeys: model for studying malaria-induced anemia
    Andrea F Egan
    Malaria Vaccines Section and Malaria Vaccine Development Unit, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 99:3863-6. 2002
    ..We demonstrate that Aotus monkeys are a nonhuman primate model to gain insight into the pathogenesis of severe anemia in African children...
  31. ncbi request reprint Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria
    Elissa M Malkin
    Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5640 Fishers Lane, Twinbrook 1, Room 1123, Rockville, MD 20852, USA
    Vaccine 23:3131-8. 2005
    ..Pvs25H generates transmission blocking immunity in humans against P. vivax demonstrating the potential of this antigen as a component of a transmission blocking vaccine...
  32. ncbi request reprint Progress in the development of recombinant and synthetic blood-stage malaria vaccines
    Siddhartha Mahanty
    Malaria Vaccine Development Unit, NIAID, NIH, Twin Brook I, 5640 Fishers Lane, Rockville, MD 20852, USA
    J Exp Biol 206:3781-8. 2003
    ..Results from trials of asexual blood stage vaccine that support the continued effort to develop these antigens as key ingredients of multicomponent, multistage malaria vaccines are documented...
  33. pmc Development of a Direct Alhydrogel Formulation Immunoassay (DAFIA)
    Daming Zhu
    Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Disease, National Institutes of Health, Rockville, MD 20852, USA
    J Immunol Methods 344:73-8. 2009
    ....
  34. pmc A Phase 1 study of the blood-stage malaria vaccine candidate AMA1-C1/Alhydrogel with CPG 7909, using two different formulations and dosing intervals
    Ruth D Ellis
    Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Twinbrook I, MD 20852, USA
    Vaccine 27:4104-9. 2009
    ..037, 95% CI 1.03, 4.28). In vitro growth inhibition followed the antibody level: median inhibition was 51% (0,1 month interval) versus 85% (0,2 month interval) in antibody from samples taken 2 weeks post-second vaccination (p=0.056)...
  35. ncbi request reprint Montanide ISA 720 vaccines: quality control of emulsions, stability of formulated antigens, and comparative immunogenicity of vaccine formulations
    Aaron P Miles
    Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5640 Fishers Lane, Twinbrook I Room 1118, Rockville, MD 20852, USA
    Vaccine 23:2530-9. 2005
    ....
  36. pmc Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria
    Elissa M Malkin
    Johns Hopkins University Bloomberg School of Public Health, Center for Immunization Research, 624 N Broadway, Room 217, Baltimore, MD 21205, USA
    Infect Immun 73:3677-85. 2005
    ..To our knowledge, this is the first AMA1 vaccine candidate to elicit functional immune responses in malaria-naive humans, and our results support the further development of this vaccine...
  37. pmc Use of o-phthalaldehyde assay to determine protein contents of Alhydrogel-based vaccines
    Daming Zhu
    Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Disease, National Institutes of Health, 5640 Fishers Lane, Rockville, MD 20852, USA
    Vaccine 27:6054-9. 2009
    ..25-500 microg/mL). This assay has proven to be highly useful in our laboratory and been used in routine vaccine quality control processes...
  38. ncbi request reprint Crystallization and preliminary X-ray analysis of the Plasmodium vivax sexual stage 25 kDa protein Pvs25, a transmission-blocking vaccine candidate for malaria
    Ajay K Saxena
    Structural Biology Section, Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Twinbrook II, 12441 Parklawn Drive, Rockville, Maryland 20852, USA
    Acta Crystallogr D Biol Crystallogr 60:706-8. 2004
    ..3 A, beta = 104.0 degrees which was predicted to have one or two molecules in the asymmetric unit. Several native and heavy-atom data sets have been collected from Pvs25 and methylated Pvs25 crystals for use in MAD or MIR techniques...
  39. pmc Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51
    Yimin Wu
    Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, Rockville, Maryland, United States of America
    PLoS ONE 3:e2636. 2008
    ..This single blinded, dose escalating, controlled Phase 1 study assessed the safety and immunogenicity of recombinant Pfs25 and Pvs25 formulated with Montanide ISA 51, a water-in-oil emulsion...
  40. pmc Assessment of the humoral immune response against Plasmodium falciparum rhoptry-associated proteins 1 and 2
    A Stowers
    ACITHN and CRC for Vaccine Technology, Queensland Institute of Medical Research, Brisbane, Australia
    Infect Immun 65:2329-38. 1997
    ..For all antigens tested, antibody levels after two infections can approach the peak levels of antibodies obtained in immune individuals...
  41. ncbi request reprint Mapping of conformational B cell epitopes within alpha-helical coiled coil proteins
    J A Cooper
    Cooperative Research Centre for Vaccine Technology and Queensland Institute of Medical Research, Herston, Brisbane, Australia
    Mol Immunol 34:433-40. 1997
    ..This approach has the potential to map conformational epitopes and design minimal epitopes for use as vaccine candidates...
  42. ncbi request reprint Extraction and characterization of vaccine antigens from water-in-oil adjuvant formulations
    Aaron P Miles
    Biochemical Assay Development and Quality Control, Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, Rockville, MD, USA
    Methods Mol Biol 308:293-300. 2005
  43. ncbi request reprint Twin study of adolescent genetic susceptibility to mosquito bites using ordinal and comparative rating data
    K M Kirk
    The Queensland Institute of Medical Research and Joint Genetics Program, The University of Queensland, Brisbane, Australia
    Genet Epidemiol 19:178-90. 2000
    ..Comparative rating questionnaire items are a potentially valuable tool for complementing and improving the results obtained from more conventional absolute measures...
  44. ncbi request reprint Anti-malarial effect of histone deacetylation inhibitors and mammalian tumour cytodifferentiating agents
    K T Andrews
    The Queensland Institute of Medical Research, PO Royal Brisbane Hospital, 300 Herston Road, Queensland 4029, Brisbane, Australia
    Int J Parasitol 30:761-8. 2000
    ..These results suggest a promising role for histone deacetylase inhibitors and cytodifferentiating agents as antimalarial drug candidates...
  45. ncbi request reprint Revisiting Freund's incomplete adjuvant for vaccines in the developing world
    Louis H Miller
    Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Twinbrook 1, 5640 Fishers Lane, Rockville, MD 20818, USA
    Trends Parasitol 21:412-4. 2005
    ....
  46. ncbi request reprint Determining residual host cell antigen levels in purified recombinant proteins by slot blot and scanning laser densitometry
    Aaron P Miles
    Biochemical Assay Development and Quality Control, Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, Rockville, MD, USA
    Methods Mol Biol 308:233-42. 2005
  47. ncbi request reprint Quantifying recombinant proteins and their degradation products using SDS-PAGE and scanning laser densitometry
    Aaron P Miles
    Biochemical Assay Development and Quality Control, Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, Rockville, MD, USA
    Methods Mol Biol 308:349-56. 2005
  48. ncbi request reprint Production and characterization of clinical grade Escherichia coli derived Plasmodium falciparum 42 kDa merozoite surface protein 1 (MSP1(42)) in the absence of an affinity tag
    Richard L Shimp
    Malaria Vaccine Development Branch MVDB, NIAID NIH DHHS, Rockville, MD, USA
    Protein Expr Purif 50:58-67. 2006
    ..A final recovery of 87.8 mg of clinical-grade material per liter of fermentation broth was achieved. The EcMSP1(42)-FUP clinical antigen is available for preclinical evaluation and human studies...
  49. ncbi request reprint Year-to-year variation in the age-specific incidence of clinical malaria in two potential vaccine testing sites in Mali with different levels of malaria transmission intensity
    Alassane Dicko
    Malaria Research and Training Center, Department of Epidemiology of Parasitic Diseases, Faculty of Medicine, Pharmacy and Odonto Stomatology, University of Bamako, Bamako, Mali
    Am J Trop Med Hyg 77:1028-33. 2007
    ..Our results suggest that, although the age distribution of clinical malaria depends on transmission intensity, the total burden of disease may be similar or higher in settings of low transmission...
  50. pmc Impact of a Plasmodium falciparum AMA1 vaccine on antibody responses in adult Malians
    Alassane Dicko
    Malaria Research and Training Center, Department of Hematology, University of Bamako, Bamako, Mali
    PLoS ONE 2:e1045. 2007
    ..After a peak 14 days following the second vaccination, antibody levels decreased to baseline levels one year later at the time of the third vaccination that induced little or no increase in antibody levels...
  51. ncbi request reprint The mosquito's innate sting
    Allan Saul
    Nat Med 10:455-7. 2004
  52. pmc Strain-specific humoral response to a polymorphic malaria vaccine
    Christian Flück
    Swiss Tropical Institute, Socinstrasse 57, Basel
    Infect Immun 72:6300-5. 2004
    ..These findings support the inclusion of both family-specific domains (3D7 and FC27) in an improved vaccine formulation...
  53. ncbi request reprint Progress and challenges for malaria vaccines
    Thomas L Richie
    Malaria Program, Naval Medical Research Center, 503 Robert Grant Avenue, Silver Spring, Maryland 20910 7500, USA
    Nature 415:694-701. 2002
    ..What are the reasons for the slow rate of progress, and what has been learned from the first clinical trials of candidate malaria vaccines? What are the remaining challenges, and what strategies can be pursued to address them?..
  54. pmc Phase 1 study of a combination AMA1 blood stage malaria vaccine in Malian children
    Alassane Dicko
    Malaria Research and Training Center, Department of Epidemiology of Parasitic Diseases, Faculty of Medicine, Pharmacy and Dentistry, University of Bamako, Bamako, Mali
    PLoS ONE 3:e1563. 2008
    ..The aim of this study was to assess the safety and immunogenicity of this vaccine in young children in a malaria endemic area...
  55. ncbi request reprint A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea
    Blaise Genton
    Papua New Guinea Institute of Medical Research, Maprik, Papua New Guinea
    J Infect Dis 185:820-7. 2002
    ..The vaccine-induced selection pressure exerted on the parasites and its consequences for morbidity strongly argue for developing vaccines comprising conserved antigens and/or multiple components covering all important allelic types...
  56. pmc Human leukocyte antigen class II alleles influence levels of antibodies to the Plasmodium falciparum asexual-stage apical membrane antigen 1 but not to merozoite surface antigen 2 and merozoite surface protein 1
    Armead H Johnson
    Departments of Pediatrics, Georgetown University, Washington, DC 20057, USA
    Infect Immun 72:2762-71. 2004
    ....
  57. ncbi request reprint Update on the clinical development of candidate malaria vaccines
    W Ripley Ballou
    Clinical Research and Development, and Research and Development, GlaxoSmithKline Biologicals, Rixensart, Belgium
    Am J Trop Med Hyg 71:239-47. 2004
    ..They focus their comments on those candidate vaccines that are currently in or expected to enter clinical trials in the next 12 months...
  58. ncbi request reprint Safety and immunogenicity of a three-component blood-stage malaria vaccine (MSP1, MSP2, RESA) against Plasmodium falciparum in Papua New Guinean children
    Blaise Genton
    PNG Institute of Medical Research, Maprik, Papua, New Guinea
    Vaccine 22:30-41. 2003
    ..Vaccine immunogenicity was neither impaired by circulating parasites nor increased after pre-treatment with SP and pre-treatment is not advisable in future trials of malaria vaccines, at least for those including blood-stage antigens...
  59. ncbi request reprint Induction of transmission-blocking immunity in Aotus monkeys by vaccination with a Plasmodium vivax clinical grade PVS25 recombinant protein
    Myriam Arevalo-Herrera
    Instituto de Inmunología del Valle, Universidad del Valle, Cali, Colombia
    Am J Trop Med Hyg 73:32-7. 2005
    ..In conclusion, Pvs25 protein formulated in Montanide ISA-720 induces efficient and long-lasting transmission-blocking antibodies that cannot be boosted by parasite infection...
  60. ncbi request reprint Assessment of transmission-blocking activity of candidate Pvs25 vaccine using gametocytes from chimpanzees
    William E Collins
    Malaria Branch, Division of Parasitic Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
    Am J Trop Med Hyg 74:215-21. 2006
    ..vivax derived from infections induced in chimpanzees can contribute to the selection of appropriate constructs, formulations, and immunization regimens for the development of effective transmission-blocking vaccines...
  61. ncbi request reprint Alterations in Plasmodium falciparum genotypes during sequential infections suggest the presence of strain specific immunity
    Damon P Eisen
    Department of Microbiology, Monash University, Clayton, Victoria, Australia
    Am J Trop Med Hyg 67:8-16. 2002
    ..This strain was predominant at the first time point but had disappeared at the fourth time point. This significant change in malaria genotypes could be due to strain-specific immunity developing in this population...
  62. ncbi request reprint Potency assay design for adjuvanted recombinant proteins as malaria vaccines
    Birgitte K Giersing
    PATH Malaria Vaccine Initiative MVI, Bethesda, MD 20814, USA
    Vaccine 24:4264-70. 2006
    ..The aim of this meeting was to produce a discussion document on the practical potency assessment of recombinant protein malaria vaccines, focusing on early phase potency assay development...
  63. ncbi request reprint The use of transgenic Plasmodium berghei expressing the Plasmodium vivax antigen P25 to determine the transmission-blocking activity of sera from malaria vaccine trials
    Souraya Ramjanee
    Division of Cell and Molecular Biology, Sir Alexander Fleming Building, Imperial College London, Imperial College Road, London SW7 2AZ, UK
    Vaccine 25:886-94. 2007
    ..To this end the cloned lines have been deposited with, and are freely available from, MR4...
  64. ncbi request reprint Malaria vaccines based on the Plasmodium falciparum merozoite surface protein 3--should we avoid amino acid sequence polymorphisms or embrace them?
    Allan Saul
    J Infect Dis 195:171-3. 2007
  65. ncbi request reprint Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum
    David J Pombo
    Queensland Institute of Medical Research, Australian Centre for International and Tropical Health and Nutrition, and Cooperative Research Centre for Vaccine Technology, PO Royal Brisbane Hospital, Australia
    Lancet 360:610-7. 2002
    ..Our aim was to ascertain whether or not development of cell-mediated immunity to Plasmodium falciparum blood-stage infection could be induced in human beings by exposure to malaria parasites in very low density...
  66. pmc High diversity and rapid changeover of expressed var genes during the acute phase of Plasmodium falciparum infections in human volunteers
    Jennifer Peters
    Malaria Laboratory, Infectious Diseases Unit, Queensland Institute of Medical Research, Post Office Royal Brisbane Hospital, Queensland 4029, Australia
    Proc Natl Acad Sci U S A 99:10689-94. 2002
    ....
  67. ncbi request reprint Ten families of variant genes encoded in subtelomeric regions of multiple chromosomes of Plasmodium chabaudi, a malaria species that undergoes antigenic variation in the laboratory mouse
    Katja Fischer
    The Queensland Institute of Medical Research, P O Royal Brisbane Hospital, Australia
    Mol Microbiol 48:1209-23. 2003
    ..Although all families have homologues in other rodent Plasmodium species, four were previously not known to be subtelomeric. Six have homologues in human and simian malarias...
  68. ncbi request reprint Dissecting the EphA3/Ephrin-A5 interactions using a novel functional mutagenesis screen
    Fiona M Smith
    Leukaemia Foundation of Queensland Laboratory, Queensland Institute of Medical Research, P O Royal Brisbane Hospital, Queensland 4029, Australia
    J Biol Chem 279:9522-31. 2004
    ..Functional analysis of EphA3 mutants reveals that all three Eph/ephrin contact areas are essential for the assembly of signaling-competent, oligomeric receptor-ligand complexes...
  69. pmc Mutations in cytochrome b resulting in atovaquone resistance are associated with loss of fitness in Plasmodium falciparum
    Jennifer M Peters
    Malaria Laboratory, Infectious Diseases Unit, The Queensland Institute of Medical Research, Queensland, Australia
    Antimicrob Agents Chemother 46:2435-41. 2002
    ..Our results suggest that the prevalence of resistant parasites may decrease after the drug usage is discontinued...